PRAME gene expression in acute leukemia and its clinical significance

Cancer Biology and Medicine

Volumn 9, Issue 1, 2012, Pages 73-76

  Ding, Kai ^a   Wang, Xiao Ming ^a   Fu, Rong ^a   Ruan, Er Bao ^a   Liu, Hui ^a   Shao, Zong Hong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Acute leukemia; Gene; Immunotherapy; Minimal residual disease; Preferentially expressed antigen of melanoma

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CD64 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; KARYOTYPE; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MALE; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

EID: 84876343273     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-3941.2012.01.013     Document Type: Article

References (13)

1. Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208.
2. Matsushita M, Ikeda H, Kizaid M, et al, Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukemia. Br J haematol 2001; 112: 916-926.
3. Güre AO, Stockert E, Arden KC, et al. CT10: A new cancertestis (CT) antigen homologous to CT17 and the MAGE family, identified by representational-difference analysis. Int J Cancer 2000; 85: 726-732.
4. Paydas S, Tanriverdi K, Yavuz S, et al. PRAME mRNA Levels in Cases With Acute Leukemia: Clinical Importance and Future Prospects. Am J Hematol 2005; 79: 257-261.
5. van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells. Br J Haematol 1998; 102: 1376-1379.
6. Steinbach D, Hemann J, Viehmann S, et al. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002; 133: 118-123.
7. Qin Y, Zhu H, Jiang B, et al. Expression patterns of WT1 and PRAME in acute myeloid Leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009, 33: 384-390.
8. Xu KH, Yang GY, Huang ZG, et al. The expression of PRAME gene in acute leukemia and its clinical significance compared with WT1 gene. Linchuang Xu Ye Xue Za Zhi 2002; 16: 113-115 (in Chinese).
9. Epping MT, Wang L, Edel MJ, et al. The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling. Cell 2005; 122: 835-847.
10. Oehler VG, Guthrie KA, Cummings CL, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009; 114: 3299-3308.
11. Costessi A, Mahrour N, Tijchon E, et al. The tumor antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J 2011; 30: 3786-3798.
12. Oehler VG, Guthrie KA, Cummings CL, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009, 114; 3299-3308.
13. Rezvani K, Yong AS, Tawab A, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009; 113: 2245-2255.